Skip to content

To evaluate the clinical mechanism of Lian-Hua Qing-Wen capsule on systemic immune regulation of influenza patients

To evaluate the clinical mechanism of Lian-Hua Qing-Wen capsule on systemic immune regulation of influenza patients

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005453
Enrollment
Unknown
Registered
2021-12-27
Start date
2022-01-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

influenza

Interventions

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Meet the influenza clinical diagnosis criteria of Influenza Diagnosis and Treatment Protocol (2020 Edition); 2.18 = age < 70; 3. Fever duration =48h, maximum axillary temperature =38.5?; 4. Pharyngeal swabs tested positive for influenza virus rapid antigen. 5. Signed the informed consent, and the informed consent process was in accordance with the provisions. 6. Flu patients who have received COVID-19 vaccine for more than a month.

Exclusion criteria

Exclusion criteria: 1. Comply with the "epidemic cold diagnosis and treatment plan (2020 edition)" influenza clinical diagnosis criteria; 2.18 years old = age <70 years old; 3. The heating process is =48h, the highest underarm temperature = 38.5 ° C; 4. Positive antigen detection of throat swab influenza virus; 5. Sign the informed consent, the informed consent process meets the requirements; 6. Injection of neoguan vaccine patients more than 1 month of flu patients.

Design outcomes

Primary

MeasureTime frame
Inflammatory factors;Immune cell genus;

Countries

China

Contacts

Public ContactYe Jing
carlionje8@126.com18121263409

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026